The Quantellect read.As of Nov 19, 2026, 8 active firms cover Halozyme Therapeutics Inc: 6 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $78.00 to $130.00, a moderate spread. The average target of $102.38 sits 7% above the current $95.81. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.33 next quarter toward $10.59 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy675%
Neutral225%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$102.38
+6.9% upside
Average target across 8 active firms as of Nov 19, 2026 vs $95.81 current
Highest Target$130.00
Average Target$102.38
Lowest Target$78.00
Detailed analyst forecasts for HALO
Showing 1–8 of 8 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 6 of 8 active firms rate HALO a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
HALO EPS & revenue forecast
EPS · NEXT QUARTER
$2.33
Range $2.32 – $2.34 · 3 analysts · +46% YoY
Next period, 3 analysts expect Halozyme Therapeutics Inc to earn $2.33 a share (range $2.32 – $2.34), versus $1.60 a year earlier. Full-year consensus is $8.89, growing to $10.59 the year after.
REVENUE · NEXT QUARTER
$488.7M
Range $478.0M – $499.4M · 3 analysts · +30% YoY
Revenue is expected to reach $488.7M (range $478.0M – $499.4M), +29.7% year-over-year. Full-year consensus is $1.9B, rising to $2.2B next year.
Top analysts covering Halozyme Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HALO.
#1
Jason Butler
JMP Securities · Rank #62
Buy
$93.00-2.9% to target
Overall win rate
49%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #100
Neutral
$79.00-17.5% to target
Overall win rate
54%
+ Follow
#3
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Buy
$130.00+35.7% to target
Overall win rate
33%
+ Follow
#4
RW
Robert Wasserman
Benchmark · Rank #388
Buy
$90.00-6.1% to target
Overall win rate
41%
+ Follow
#5
BS
Brendan Smith
TD Cowen
Buy
$130.00+35.7% to target
Coverage
—
+ Follow
HALO stock forecast FAQ
What is HALO's average 12-month price target?+
The 8 active firms with a live target average $102.38 for Halozyme Therapeutics Inc over the next 12 months, ranging from a $130.00 high to a $78.00 low, as of Nov 19, 2026.
Is HALO stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for HALO?+
The Street-high target is $130.00 (TD Cowen), and the Street-low is $78.00 (JP Morgan). The average of all 8 active-firm targets is $102.38.
How many active Wall Street firms cover HALO?+
8 active firms have a recognized rating on Halozyme Therapeutics Inc as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering HALO?+
Among analysts who currently cover HALO, Jason Butler of JMP Securities has the strongest overall Quantellect track record (Rank #62). Their current call is Buy with a $93.00 target.
What is Halozyme Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $2.33 per share (range $2.32 – $2.34) across 3 analysts. Full-year EPS is projected at $8.89, rising to $10.59 the following year.
How much revenue is Halozyme Therapeutics Inc expected to report next quarter?+
Consensus revenue is $488.7M (range $478.0M – $499.4M). Full-year revenue is projected at $1.9B, growing to $2.2B next year.
Have analysts been upgrading or downgrading HALO lately?+
As of Nov 19, 2026, 6 of 8 active firms rate HALO a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HALO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.